CNTX Similar Chart Price Prediction
The price of CNTX is predicted to go up -22.22%, based on the high correlation periods with OPK. The similarity of these two price pattern on the periods is 92.24%.
CNTX
OPK
Down: -22.22%Similarity: 92.24%
CNTX Revenue Forecast
CNTX EPS Forecast
CNTX Analyst's Forecast
Silvan Tuerkcan
JMP Securities
Buy
2025-01-08
Price Target
$4
Upside
+230.58%
JMP Securities initiated coverage of Context Therapeutics with an Outperform rating and $4 price target. Context is a $97.8M market cap clinical-stage biotechnology company focused on developing next-generation T cell engaging bispecific antibody therapies to treat solid tumors, the analyst tells investors in a research note. The firm says the company is building an "innovative" portfolio of in-licensed clinical-stage TCE bispecific antibodies. It views the management team as "highly effective business development operators that have built a pipeline through opportunistic in-licensing of the three early-stage assets that are worth more than the sum of its parts."
Jason Kolbert
D. Boral Capital
Strong Buy
2024-11-25
Price Target
$9
Upside
+516.44%
